Swiss National Bank increased its holdings in TherapeuticsMD Inc (NASDAQ:TXMD) by 3.5% during the second quarter, Holdings Channel.com reports. The firm owned 381,400 shares of the company’s stock after acquiring an additional 12,900 shares during the quarter. Swiss National Bank’s holdings in TherapeuticsMD were worth $1,003,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of TXMD. JPMorgan Chase & Co. boosted its stake in shares of TherapeuticsMD by 3.0% during the first quarter. JPMorgan Chase & Co. now owns 20,435,672 shares of the company’s stock valued at $99,521,000 after purchasing an additional 601,899 shares during the period. FMR LLC increased its position in shares of TherapeuticsMD by 0.5% in the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after acquiring an additional 89,870 shares during the period. Frontier Capital Management Co. LLC raised its stake in shares of TherapeuticsMD by 291.5% during the first quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after acquiring an additional 4,360,963 shares during the last quarter. Rubric Capital Management LP raised its stake in shares of TherapeuticsMD by 203.6% during the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock valued at $22,845,000 after acquiring an additional 3,145,742 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its holdings in shares of TherapeuticsMD by 222.3% during the second quarter. C WorldWide Group Holding A S now owns 3,189,834 shares of the company’s stock worth $8,294,000 after purchasing an additional 2,200,000 shares during the period. Institutional investors own 78.88% of the company’s stock.
TXMD stock traded up $0.03 during trading on Wednesday, reaching $3.33. The company had a trading volume of 43,174 shares, compared to its average volume of 2,388,504. TherapeuticsMD Inc has a 52 week low of $1.82 and a 52 week high of $6.94. The company has a market cap of $807.87 million, a P/E ratio of -5.64 and a beta of 1.70. The business has a 50 day moving average of $2.62 and a 200 day moving average of $3.58. The company has a debt-to-equity ratio of 24.29, a current ratio of 5.17 and a quick ratio of 4.99.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The firm had revenue of $6.08 million for the quarter, compared to the consensus estimate of $5.12 million. During the same period in the previous year, the firm posted ($0.15) earnings per share. The business’s revenue was up 60.0% compared to the same quarter last year. Research analysts expect that TherapeuticsMD Inc will post -0.73 earnings per share for the current year.
A number of research analysts recently issued reports on the company. Jefferies Financial Group reduced their price target on TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Monday, July 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of TherapeuticsMD in a report on Wednesday, August 7th. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. reduced their target price on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, June 11th. Finally, BidaskClub upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and a consensus price target of $9.16.
In other TherapeuticsMD news, CEO Robert G. Finizio purchased 35,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at an average cost of $2.74 per share, with a total value of $95,900.00. Following the transaction, the chief executive officer now directly owns 18,253,964 shares in the company, valued at approximately $50,015,861.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Angus C. Russell bought 10,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were acquired at an average price of $2.77 per share, with a total value of $27,700.00. Following the completion of the acquisition, the director now directly owns 93,500 shares of the company’s stock, valued at approximately $258,995. The disclosure for this purchase can be found here. Insiders bought a total of 170,549 shares of company stock valued at $493,167 in the last three months. Corporate insiders own 18.91% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Recommended Story: Mutual Funds
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.